Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$2.41 USD
+0.02 (0.67%)
Updated Jun 17, 2024 03:42 PM ET
After-Market: $2.34 -0.07 (-2.75%) 7:36 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
COCP 2.41 +0.02(0.67%)
Will COCP be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for COCP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COCP
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
COCP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for COCP
Noble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP)
Cocrystal Pharma: A Strong Buy on Innovative Antiviral Pipeline and Market Potential
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024
Cocrystal Pharma GAAP EPS of -$0.39 beats by $0.15
Cocrystal Pharma reports Q1 EPS (39c) vs (64c) last year